Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Anavex Life Sciences Corp AVXL

Healthcare Biotechnology
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:AVXL)

Anavex's Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer's Trial: Data Presented at CTAD Conference 2024

GlobeNewswire October 31, 2024

Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

GlobeNewswire October 17, 2024

Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024

GlobeNewswire September 3, 2024

Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update

GlobeNewswire August 6, 2024

Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024

GlobeNewswire August 1, 2024

Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference

GlobeNewswire July 30, 2024

Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference

GlobeNewswire July 28, 2024

Lifshitz Law PLLC Announces Investigations of Palo Alto Networks, Inc. (NASDAQ: PANW), Lyft, Inc. (NASDAQ: LYFT), Anavex Life Sciences Corporation (NASDAQ: AVXL), and GrafTech International Ltd. (NYSE: EAF)

Accesswire June 25, 2024

Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

GlobeNewswire June 20, 2024
View More News ››

Opinion & Analysis (NDAQ:AVXL)

Analyst Believes Biopharma's Alzheimer's Treatment Could Be Superior to Biogen's

Streetwise Reports December 11, 2019

EMA Opinion Bodes Well for Biopharma's Drug Getting Orphan Status

Streetwise Reports August 1, 2019
View More Opinion ››

Bullboard Posts (NDAQ:AVXL)

Not a lot of respect here….

For their data.  Seems like everyone is doubting efficacy.  But the approved products are NG also?  Well if the pharma...
hoffbag - November 25, 2023

$AVXL ANAVEX 2-73: A POTENTIAL BLOCKBUSTER DRUG IN THE MAKIN

$AVXL ANAVEX 2-73: A POTENTIAL BLOCKBUSTER DRUG IN THE MAKING!   https://www.aviseanalytics.com/anavex2-73-a-potential...
AviseAnalytics - June 30, 2021

AVXL 5 MOST PROMISING ALZHEIMER’S DISEASE STOCK!

5 MOST PROMISING ALZHEIMER’S DISEASE STOCK! https://www.aviseanalytics.com/5-most-promising-alzheimers-disease-stock/ ...
AviseAnalytics - June 22, 2021

ALL ABOARD

Dont miss this train leaving the station.............
billybob22 - February 4, 2021

End of Month - September 2020

End of the Month (EOM) report for November 2020 for Anavex Life Sciences Corp. - AVXL closed on 10/30/2020 at US$5.33 AVXL closed on 10...
R_J_ - December 2, 2020

End of Month - October 2020

End of the Month (EOM) report for October 2020 for Anavex Life Sciences Corp. - AVXL closed on 10/30/2020 at US$5.90 AVXL closed on 09/30...
R_J_ - October 31, 2020
View more Bullboard ››

Calima Energy Ord Shs

Calima Energy Ord Shs

Calima Energy Limited is an Australia-based production-focused energy company. The Company is engaged in the exploration and ...
View More »